Yu Hao, CEO of Dreame Technology, responded to the controversy: building a company worth hundreds of trillions of US dollars is the goal for the next two decades.

①Recently, Yu Hao, founder and CEO of Dreame Technology, stated in a social media post that the Dreame ecosystem would become the first company ecosystem in human history to reach a scale of one hundred trillion US dollars, drawing widespread public attention; ②Today, Yu Hao publicly responded to the recent controversy surrounding the goal of "building a one-hundred-trillion-dollar company," clarifying that this objective is a twenty-year target.

cls.cn19:12

Farewell to going it alone! The National Healthcare Security Administration is paving the way for the establishment of an overseas platform. How can pharmaceutical and medical device companies capitalize on this wave of benefits?

① The National Healthcare Security Administration encourages and guides regions with the necessary conditions to explore the establishment of a global innovative drug trading platform targeting Southeast Asia, Central Asia, and other countries; ② The “Ningbo Central and Eastern Europe (Centralized Procurement) Trading Platform” is under preparation, while medical device export platforms in Tianjin, Xinjiang, Guangxi, and other regions are ready to launch; ③ Hengrui, Qilu, and Yifan believe that going global is an inevitable path for China’s pharmaceuticals and medical devices industries, and official guidance will provide strong support for enterprises.

cls.cn19:04

Semiconductor packaging and testing concept stocks surged over 30% in two days. A list of A-share companies disclosing M&A restructuring progress this week is provided.

① The CSRC meeting emphasized stimulating the vitality of the M&A market and improving the full-chain supervision of restructuring. ② According to incomplete statistics, a total of 19 A-share listed companies disclosed the progress of M&A restructuring this week (see attached table).

cls.cn17:23

Weekend Reading | Core Investment Theme for Pharmaceuticals in 2026: Shifting from 'BD Expectation Trading' to 'Delivering Certainty'

Looking back at 2025, the wave of "BD supremacy" swept through China's pharmaceutical investment market. At that time, outbound licensing deals by innovative drug companies became the core logic driving capital inflows, reflecting the market's maximum realization of the future value of innovative pipelines.

Brocade16:27

Cui Dongshu: In 2025, vehicle exports by automotive companies will be exceptionally strong! Exports of domestically produced vehicles increased by 21% year-on-year.

In 2025, China's automobile exports demonstrated the core characteristics of 'increased volume and value, structural optimization.' The total export volume of domestically produced vehicles by automobile manufacturers for the entire year reached 7.1 million units, representing a year-on-year increase of 21%.

Zhitong Finance14:32

Breaking: Vice General Manager of a 5 billion communication equipment stock under investigation by the CSRC | Post-market announcements summary

Northern Rare Earth: Net profit for 2025 is expected to increase by 117%-135% year-on-year, driven by the year-on-year growth in production and sales of rare earth metals and rare earth permanent magnet motors.

cls.cnJan 16 20:51